The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Clinical consequences of cytochrome P450 2C9 polymorphisms
Abstract
The gene coding for the cytochrome P450 (CYP) enzyme 2C9 (CYP2C9) carries numerous inherited polymorphisms. Those coding for R144C (*2) and I359L (*3) amino acid substitutions have both significant functional effects and appreciable high population frequencies, and their in vivo consequences have been studied in humans with regard to drug metabolism. This review summarizes present knowledge about the pharmacokinetics, drug responses, and outcomes of clinical studies in individuals with different CYP2C9 genotypes. Tentative estimates of how CYP2C9 genotyping might be applied to dose adjustments in clinical therapy were based on dose-related pharmacokinetic parameters such as clearance or trough drug concentrations. Mean clearances in homozygous carriers of the *3 allele were below 25% of that of the wild type for S -warfarin, tolbutamide, glipizide, celecoxib, and fluvastatin. In the more frequent heterozygous carriers (genotype *1/*3), the clearances were between 40% and 75%. In these cases in which individual dosages are derived from clinical drug effects, such as for the oral anticoagulants, the pharmacogenetics-based dose adjustments showed a good correlation with the genotype-specific empirically derived doses. In addition to its role in pharmacokinetics, CYP2C9 contributes to the metabolism of fatty acids, prostanoids, and steroid hormones, and it may catalyze potentially toxic bioactivation reactions. However, our current understanding of the role of CYP2C9 in biotransformation of endogenous signaling molecules and in drug toxicity is relatively meager.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Ferenci, P., Lockwood, A., Mullen, K., Tarter, R., Weissenborn, K., & Blei, A. T. (2002) · Hepatology · doi:10.1053/jhep.2002.31250 · Cited by 2,043
Viral Hepatitis and Liver Disease
Vyas, G. N., Dienstag, J. L., & Hoofnagle, J. H. (1985) · Medical Entomology and Zoology · Cited by 1,860
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Alter, M. J. (1997) · Hepatology · doi:10.1002/hep.510260711 · Cited by 1,075
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea
Mueller, C., Scholer, A., Laule-Kilian, K., Martina, B., Schindler, C., Buser, P., Pfisterer, M., & Perruchoud, A. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031681 · Cited by 1,000
Crystal structure of human cytochrome P450 2C9 with bound warfarin
Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinković, D., & Jhoti, H. (2003) · Nature · doi:10.1038/nature01862 · Cited by 821
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Neuropsychological characterization of hepatic encephalopathy
Weissenborn, K., Ennen, J. C., Schomerus, H., Rückert, N., & Hecker, H. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00026-5 · Cited by 796
Cytokines and the Brain: Implications for Clinical Psychiatry
Kronfol, Z., & Remick, D. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.683 · Cited by 784
Passage of cytokines across the blood–brain barrier
Banks, W. A., Kastin, A. J., & Broadwell, R. D. (1996) · Neuroimmunomodulation · doi:10.1159/000097202 · Cited by 778
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200204000-00010 · Cited by 686
Cytokine-to-brain communication: A review & analysis of alternative mechanisms
Watkins, L. R., Maier, S. F., & Goehler, L. E. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02047-m · Cited by 597
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00007 · Cited by 582
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease
Forton, D. M., Thomas, H. C., Murphy, C. A., Allsop, J. M., Foster, G. R., Main, J., Wesnes, K. A., & Taylor-Robinson, S. D. (2002) · Hepatology · doi:10.1053/jhep.2002.30688 · Cited by 450
Taube, J., Halsall, D., & Baglin, T. (2000) · Blood · doi:10.1182/blood.v96.5.1816 · Cited by 392
Scordo, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
CYP2C9 allelic variants: ethnic distribution and functional significance
Xie, H.-G., Prasad, H. C., Kim, R. B., & Stein, C. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00076-5 · Cited by 338
Evidence for a cerebral effect of the hepatitis C virus
Forton, D. M., Allsop, J. M., Main, J., Foster, G. R., Thomas, H. C., & Taylor-Robinson, S. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05270-3 · Cited by 333
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., & Rettie, A. E. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00004 · Cited by 303
Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus
Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00264-1 · Cited by 284
Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., & Idle, J. R. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00008 · Cited by 278
Interindividual variability in sensitivity to warfarin-Nature or nurture?
Loebstein, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117444 · Cited by 260
Aynacioglu, S., Brockmöller, J., Bauer, S., Sachse, C., Güzelbey, P., Öngen, Z., Nacak, M., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00012.x · Cited by 251
Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J. J., Stein, C. M., Wilkinson, G. R., & Schwarz, U. I. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23142-4 · Cited by 249
Psychiatric Symptoms in Patients With Chronic Hepatitis C Receiving Interferon Alfa-2b Therapy
Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0614 · Cited by 245
Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin
Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00008 · Cited by 236
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
Bahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01354-0 · Cited by 235
Genetic Modulation of Oral Anticoagulation with Warfarin
Colaizzo, D., D’Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E., Di Minno, G., & Margaglione, M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614114 · Cited by 233
Chou, W. H., Yan, F.-X., de Leon, J., Barnhill, J., Rogers, T., Cronin, M., Pho, M., Xiao, V., Ryder, T. B., Liu, W. W., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00019 · Cited by 226
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population
Scordo, M. G., Aklillu, E., Yasar, Dahl, M., Spina, E., & Ingelman‐Sundberg, M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01460.x · Cited by 222
Dieperink, E., Ho, S. B., Thuras, P., & Willenbring, M. L. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.2.104 · Cited by 218
Quality of life and cognitive function in hepatitis C at different stages of liver disease
Córdoba, J., Flavià, M., Jacas, C., Sauleda, S., Esteban, J. I., Vargas, V., Esteban, R., & Guardia, J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00189-2 · Cited by 214
Persistent neurotoxicity of systemically administered interferon‐alpha
Meyers, C. A., Scheibel, R. S., & Forman, A. D. (1991) · Neurology · doi:10.1212/wnl.41.5.672 · Cited by 208
Kirchheiner, J., Brockmöller, J., Meineke, I., Bauer, S., Rohde, W., Meisel, C., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122476 · Cited by 201
Self-citationThe effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
van der Weide, J., Steijns, L. S. W., van Weelden, M. J. M., & de Haan, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00002 · Cited by 199
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191
Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S., & Echizen, H. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.26a · Cited by 190
A test battery for attentional performance
(2004) · Applied Neuropsychology of Attention · doi:10.4324/9780203307014-12 · Cited by 186
Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., & Echizen, H. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90103-5 · Cited by 183
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Yasar, Ü., Forslund‐Bergengren, C., Tybring, G., Dorado, P., LLerena, A., Sjöqvist, F., Eliasson, E., & Dahl, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121216 · Cited by 183
GARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
Niemi, M., Cascorbi, I., Timm, R., Kroemer, H. K., Neuvonen, P. J., & Kivistö, K. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127495 · Cited by 173
Kirchheiner, J., Bauer, S., Meineke, I., Rohde, W., Prang, V., Meisel, C., Roots, I., & Brockmöller, J. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00004 · Cited by 169
Self-citationMichaelis, U. R., Fisslthaler, B., Medhora, M., Harder, D., Fleming, I., & Busse, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0640fje · Cited by 169
Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors
Granville, D. J., Tashakkor, B., Takeuchi, C., Gustafsson, Å. B., Huang, C., Sayen, M. R., Wentworth, P., Yeager, M., & Gottlieb, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308185100 · Cited by 167
Kitagami, T., Yamada, K., Miura, H., Hashimoto, R., Nabeshima, T., & Ohta, T. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02776-8 · Cited by 163
Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S., & Echizen, H. (1998) · Pharmacogenetics · doi:10.1097/00008571-199810000-00001 · Cited by 162
Clinical guidelines on the management of hepatitis C
Booth, J. C. L., O'Grady, J., & Neuberger, J. (2001) · Gut · doi:10.1136/gut.49.suppl_1.i1 · Cited by 161
Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14927-6 · Cited by 161
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology · doi:10.1212/wnl.45.5.947 · Cited by 160
Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T., Ohgi, S., & Otsubo, K. (2004) · Blood · doi:10.1182/blood-2003-09-3043 · Cited by 159
Holstein, A., Plaschke, A., Ptak, M., Egberts, E. ‐., El-Din, J. S., Brockmöller, J., & Kirchheiner, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02379.x · Cited by 155
Self-citationHepatotoxicity with Thiazolidinediones: Is it a Class Effect?
Scheen, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00002 · Cited by 151
Capuron, L., Ravaud, A., & Dantzer, R. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200105000-00007 · Cited by 148
Cytochrome P450 epoxygenases as EDHF synthase(s)
Fleming, I. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.11.016 · Cited by 145
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Yaşar, Ü., Lundgren, S., Eliasson, E., Bennet, A. M., Wiman, B., Fairé, U. D., & Rane, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02592-5 · Cited by 143
Effect of Interferon-beta-1b on Cognitive Functions in Multiple Sclerosis
Barak, Y., & Achiron, A. (2002) · European Neurology · doi:10.1159/000047940 · Cited by 135
Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I., & Brockmöller, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00121-8 · Cited by 135
Self-citationGenetic predisposition to acute gastrointestinal bleeding after NSAIDs use
Martínez, C., Blanco‐Fernández, G., Ladero, J. M., García‐Martín, E., Taxonera, C., Garcia-Gamito, F. J., Díaz‐Rubio, M., & Agúndez, J. A. G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705623 · Cited by 130
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites
Kirchheiner, J., St??rmer, E., Meisel, C., Steinbach, N., Roots, I., & ller, J. R. B. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00005 · Cited by 124
Self-citationKirchheiner, J., Meineke, I., Freytag, G. T. H., Meisel, C., Roots, I., & Brockmöller, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.125726 · Cited by 120
Self-citationCytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes.
Licinio, J., Kling, M. A., & Hauser, P. (1998) · PubMed · Cited by 118
Depino, A. M., Alonso, M., Ferrari, C. C., del Rey, A., Anthony, D. C., Besedovsky, H. O., Medina, J. H., & Pitossi, F. J. (2003) · Hippocampus · doi:10.1002/hipo.10164 · Cited by 117
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
Yaşar, Ü., Eliasson, E., Forslund‐Bergengren, C., Tybring, G., Gadd, M., Sjöqvist, F., & Dahl, M. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0376-7 · Cited by 115
Kirchheiner, J., Meineke, I., Steinbach, N., Meisel, C., Roots, I., & Brockmöller, J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01712.x · Cited by 113
Self-citationWarfarin dosing and cytochrome P450 2C9 polymorphisms
Johnson, F. B., Longtine, J. A., Kucher, N., Joffe, H. V., Xu, R., & Goldhaber, S. Z. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0083 · Cited by 112
Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis
Aithal, G. P., Day, C. P., Leathart, J. B. S., & Daly, A. K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200008000-00004 · Cited by 105
Visser, L. E., van Schaik, R. H., van Vliet, M., Trienekens, P. H., Smet, P. D., Vulto, A. G., Albert Hofman, D., van Duijn, C. M., & Stricker, B. H. C. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0741 · Cited by 98
Shon, J., Yoon, Y.-R., Kim, K., Lim, Y.-C., Lee, K., Park, J. Y., Cha, I., Flockhart, D. A., & Shin, J. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00005 · Cited by 88
Brenner, S. S., Herrlinger, C., Dilger, K., Mürdter, T. E., Hofmann, U., Marx, C., & Klotz, U. E. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342030-00003 · Cited by 87
CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians*1
Vianna‐Jorge, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.002 · Cited by 86
Shintani, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117367 · Cited by 82
Cytochrome P450 polymorphisms are associated with reduced warfarin dose
Freeman, B. D., Zehnbauer, B. A., McGrath, S. D., Borecki, I. B., & Buchman, T. G. (2000) · Surgery · doi:10.1067/msy.2000.107283 · Cited by 78
CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects
Soga, Y., Nishimura, F., Ohtsuka, Y., Araki, H., Iwamoto, Y., Naruishi, H., Shiomi, N., KOBAYASHI, Y., Takashiba, S., Shimizu, K., et al. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.07.018 · Cited by 74
Pharmacology of Interleukin-1 Actions in the Brain
Rothwell, N. J., & Luheshi, G. N. (1994) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60428-7 · Cited by 73
Pharmacokinetics and clinical efficacy of pioglitazone.
Hanefeld, M. (2001) · PubMed · Cited by 72
Cytochrome P 450 2C9 phenotyping using low-dose tolbutamide
Jetter, A., Kinzig‐Schippers, M., Skott, A., Lazar, A., Tomalik‐Scharte, D., Kirchheiner, J., Walchner‐Bonjean, M., Hering, U., Jakob, V., Rodamer, M., et al. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0754-z · Cited by 71
Self-citationPhenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo
Caraco, Y., Muszkat, M., & Wood, A. J. J. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00005 · Cited by 68
Leflunomide-induced acute hepatitis
Mantilla, C. S., Ortega, L. M., Agúndez, J. A. G., Fernández‐Gutiérrez, B., Ladero, J. M., & Diaz-Rubio, M. E. (2003) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.06.002 · Cited by 67
Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status
Schalekamp, T., Oosterhof, M. M., VANMEEGEN, E., VANDERMEER, F., Conemans, J. M. H., Hermans, M. H. A., Meijerman, I., & DEBOER, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.006 · Cited by 66
The Mechanisms of Immune-to-Brain Communication in Inflammation as a Drug Target
Hosoi, T., Okuma, Y., & Nomura, Y. (2002) · Current Drug Targets - Inflammation & Allergy · doi:10.2174/1568010023344599 · Cited by 63
Theunissen, E. L., Vermeeren, A., Oers, A. C. M. V., Maris, I. V., & Ramaekers, J. G. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.01874.x · Cited by 63
Acenocoumarol stabilization is delayed in CYP2C9*3 carriers
Schalekamp, T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.017 · Cited by 61
Determination of bleeding risk using genetic markers in patients taking phenprocoumon
Hummers, E., Hess, S., Adham, I. M., Papke, T., Pieske, B. M., & Kochen, M. M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0580-8 · Cited by 60
Reversible cognitive decline during high-dose α-interferon treatment
Poutiainen, E. T., Hokkanen, L., Niemi, M., & Färkkilä, M. A. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90294-1 · Cited by 58
Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations
Yaşar, Ü., Aklillu, E., Canaparo, R., Sandberg, M., Sayi, J., Roh, H., & Wennerholm, A. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0518-6 · Cited by 53
Shimamoto, J., Ieiri, I., Urae, A., Kimura, M., Irie, S., Kubota, T., Chiba, K., Ishizaki, T., Otsubo, K., & Higuchi, S. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050722 · Cited by 53
Identification of CYP2C9 as a Human Liver Microsomal Linoleic Acid Epoxygenase
Draper, A. J., & Hammock, B. D. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1705 · Cited by 47
Takahashi, H., Ieiri, I., Wilkinson, G. R., Mayo, G., Kashima, T., Kimura, S., Otsubo, K., & Echizen, H. (2004) · Blood · doi:10.1182/blood-2003-07-2521 · Cited by 46
Exton, M. S., Baase, J., Pithan, V., Goebel, M. U., Limmroth, V., & Schedlowski, M. (2002) · Neuropsychobiology · doi:10.1159/000063671 · Cited by 39
Gerschlager, W., Beisteiner, R., Deecke, L., Dirnberger, G., Endl, W., Kollegger, H., Lindinger, G., Vass, K., & Lang, W. (2000) · European Neurology · doi:10.1159/000008237 · Cited by 36
Cognitive Function and Quality of Life in Interferon Therapy for Melanoma
Bender, C. M., Yasko, J. M., Kirkwood, J. M., Ryan, C. M., Dunbar‐Jacob, J. M., & Zullo, T. G. (2000) · Clinical Nursing Research · doi:10.1177/10547730022158537 · Cited by 31
Neurological Function During Long-Term Therapy With Recombinant Interferon Alpha
Mayr, N., Zeitlhofer, J., Deecke, L., Fritz, E., Ludwig, H., & Gisslinger, H. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.3.343 · Cited by 24
Emerging Ethical Issues in Pharmacogenomics: From Research to Clinical Practice
Freund, C. L., & Wilfond, B. S. (2002) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200202040-00007 · Cited by 23
Cited by
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Metadata
- Authors
- KIRCHHEINER, J., & BROCKMOLLER, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-01
- Volume
- 77
- Issue
- 1
- Pages
- 1-16
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2109453128
- Cited by
- 474
- References
- 100
- FWCI
- 41.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.